{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:43:43Z","timestamp":1763984623023,"version":"3.45.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-03760-0","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:39:56Z","timestamp":1763984396000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A bibliometric study on microenvironment-mediated drug resistance in interventional liver cancer treatment"],"prefix":"10.1007","volume":"16","author":[{"given":"Qiang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guo","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanji","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanjie","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"issue":"3","key":"3760_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"10474","key":"3760_CR2","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S0140-6736(24)02551-0","volume":"405","author":"B Sangro","year":"2025","unstructured":"Sangro B, Kudo M, Erinjeri JP, et al. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study. Lancet. 2025;405(10474):216\u201332.","journal-title":"Lancet"},{"issue":"2","key":"3760_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3892\/ol.2024.14480","volume":"28","author":"Y Li","year":"2024","unstructured":"Li Y, Liu X, Liu J, et al. Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta-analysis. Oncol Lett. 2024;28(2):347.","journal-title":"Oncol Lett"},{"issue":"1","key":"3760_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12943-024-02062-3","volume":"23","author":"DZ Guo","year":"2024","unstructured":"Guo DZ, Zhang X, Zhang SQ, et al. Single-cell tumor heterogeneity landscape of hepatocellular carcinoma: unraveling the pro-metastatic subtype and its interaction loop with fibroblasts. Mol Cancer. 2024;23(1):157.","journal-title":"Mol Cancer"},{"key":"3760_CR5","doi-asserted-by":"crossref","unstructured":"Ning J, Ye Y, Shen H et al. Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. Cell Rep Med, 2024, 5(5).","DOI":"10.1016\/j.xcrm.2024.101505"},{"issue":"1","key":"3760_CR6","doi-asserted-by":"publisher","first-page":"14779","DOI":"10.1038\/s41598-024-65630-z","volume":"14","author":"K Bartnik","year":"2024","unstructured":"Bartnik K, Krzyzi\u0144ski M, Bartczak T, et al. A novel radiomics approach for predicting TACE outcomes in hepatocellular carcinoma patients using deep learning for multi-organ segmentation. Sci Rep. 2024;14(1):14779.","journal-title":"Sci Rep"},{"issue":"24","key":"3760_CR7","first-page":"9447","volume":"26","author":"Q Cao","year":"2022","unstructured":"Cao Q, Zhang Q, Chen YQ, et al. Risk factors for the development of hepatocellular carcinoma in chengdu: a prospective cohort study. Eur Rev Med Pharmacol Sci. 2022;26(24):9447\u201356.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"10","key":"3760_CR8","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1158\/1078-0432.CCR-24-1228","volume":"31","author":"SW Chung","year":"2025","unstructured":"Chung SW, Kim JS, Choi WM, et al. Synergistic effects of transarterial chemoembolization and lenvatinib on HIF-1\u03b1 ubiquitination and prognosis improvement in hepatocellular carcinoma. Clin Cancer Res. 2025;31(10):2046\u201355.","journal-title":"Clin Cancer Res"},{"issue":"Supplement1","key":"3760_CR9","doi-asserted-by":"publisher","first-page":"bbae236","DOI":"10.1093\/bib\/bbae236","volume":"25","author":"Y Qin","year":"2024","unstructured":"Qin Y, Maggio A, Hawkins D, et al. Whole-genome bisulfite sequencing data analysis learning module on Google cloud platform. Brief Bioinform. 2024;25(Supplement1):bbae236.","journal-title":"Brief Bioinform"},{"issue":"12","key":"3760_CR10","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1158\/0008-5472.CAN-21-0184","volume":"81","author":"HW Leung","year":"2021","unstructured":"Leung HW, Leung C, O N, Lau EY, et al. EPHB2 activates \u03b2-catenin to enhance cancer stem cell properties and drive Sorafenib resistance in hepatocellular carcinoma. Cancer Res. 2021;81(12):3229\u201340.","journal-title":"Cancer Res"},{"key":"3760_CR11","doi-asserted-by":"publisher","first-page":"1254232","DOI":"10.3389\/fmolb.2023.1254232","volume":"10","author":"H Chi","year":"2023","unstructured":"Chi H, Huang J, Yan Y, et al. Unraveling the role of disulfidptosis-related LncRNAs in colon cancer: a prognostic indicator for immunotherapy response, chemotherapy sensitivity, and insights into cell death mechanisms. Front Mol Biosci. 2023;10:1254232.","journal-title":"Front Mol Biosci"},{"issue":"4","key":"3760_CR12","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","volume":"76","author":"AL Cheng","year":"2022","unstructured":"Cheng AL, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862\u201373.","journal-title":"J Hepatol"},{"issue":"1","key":"3760_CR13","doi-asserted-by":"publisher","first-page":"6699","DOI":"10.1038\/s41467-023-42360-w","volume":"14","author":"CON Leung","year":"2023","unstructured":"Leung CON, Yang Y, Leung RWH, et al. Broad-spectrum Kinome profiling identifies CDK6 upregulation as a driver of lenvatinib resistance in hepatocellular carcinoma. Nat Commun. 2023;14(1):6699.","journal-title":"Nat Commun"},{"key":"3760_CR14","doi-asserted-by":"publisher","first-page":"1181467","DOI":"10.3389\/fimmu.2023.1181467","volume":"14","author":"G Song","year":"2023","unstructured":"Song G, Peng G, Zhang J, et al. Uncovering the potential role of oxidative stress in the development of periodontitis and Establishing a stable diagnostic model via combining single-cell and machine learning analysis. Front Immunol. 2023;14:1181467.","journal-title":"Front Immunol"},{"issue":"11","key":"3760_CR15","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.7150\/jca.95757","volume":"15","author":"R Liu","year":"2024","unstructured":"Liu R, Liu J, Cao Q, et al. Identification of crucial genes through WGCNA in the progression of gastric cancer. J Cancer. 2024;15(11):3284.","journal-title":"J Cancer"},{"key":"3760_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jconrel.2024.06.026","volume":"372","author":"Zhou Xuancheng","year":"2024","unstructured":"Zhou X, et al. Deciphering the role of acetylation-related gene NAT10 in colon cancer progression and immune evasion: implications for overcoming drug resistance. Discov Oncol. 2025;16(1):774. https:\/\/doi.org\/10.1007\/s12672-025-02617-w.","journal-title":"J Controlled Release"},{"key":"3760_CR17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.actbio.2022.12.004","volume":"157","author":"Z Zheng","year":"2023","unstructured":"Zheng Z, Ma M, Han X, et al. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomater. 2023;157:337\u201351.","journal-title":"Acta Biomater"},{"key":"3760_CR18","doi-asserted-by":"publisher","first-page":"1265959","DOI":"10.3389\/fimmu.2023.1265959","volume":"14","author":"Lai Jiang","year":"2023","unstructured":"Jiang L, et al. The key role of COA6 in pancreatic ductal adenocarcinoma: metabolic reprogramming and regulation of the immune microenvironment. J Cell Mol Med. 2025;29(13):e70685. https:\/\/doi.org\/10.1111\/jcmm.70685.","journal-title":"Front Immunol"},{"issue":"1","key":"3760_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12876-025-03861-8","volume":"25","author":"J Wang","year":"2025","unstructured":"Wang J, Shi J, Mi L, et al. Identification and validation of a lenvatinib resistance-related prognostic signature in HCC, in which PFKFB4 contributes to tumor progression and lenvatinib resistance. BMC Gastroenterol. 2025;25(1):287.","journal-title":"BMC Gastroenterol"},{"key":"3760_CR20","doi-asserted-by":"crossref","unstructured":"Li H, Guo L, Su K et al. Construction and validation of TACE therapeutic efficacy by ALR score and nomogram: a large, multicenter study. J Hepatocellular Carcinoma, 2023: 1009\u201317.","DOI":"10.2147\/JHC.S414926"},{"issue":"11","key":"3760_CR21","doi-asserted-by":"publisher","first-page":"3247","DOI":"10.1002\/hep4.2079","volume":"6","author":"M Kim","year":"2022","unstructured":"Kim M, Hui KM, Shi M, et al. Differential expression of hepatic cancer stemness and hypoxia markers in residual cancer after locoregional therapies for hepatocellular carcinoma. Hepatol Commun. 2022;6(11):3247\u201359.","journal-title":"Hepatol Commun"},{"issue":"6","key":"3760_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/j.gastro.2023.01.023","volume":"164","author":"M Lim","year":"2023","unstructured":"Lim M, Franses JW, Imperial R, et al. EGFR\/ERBB2 amplifications and alterations associated with resistance to lenvatinib in hepatocellular carcinoma. Gastroenterology. 2023;164(6):1006\u20138. e3.","journal-title":"Gastroenterology"},{"issue":"19","key":"3760_CR23","doi-asserted-by":"publisher","first-page":"10305","DOI":"10.18632\/aging.205077","volume":"15","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang H, Tang J, et al. The integrated single-cell analysis developed an Immunogenic cell death signature to predict lung adenocarcinoma prognosis and immunotherapy. Aging. 2023;15(19):10305.","journal-title":"Aging"},{"issue":"20","key":"3760_CR24","doi-asserted-by":"publisher","first-page":"3845","DOI":"10.1158\/0008-5472.CAN-21-4140","volume":"82","author":"B Hu","year":"2022","unstructured":"Hu B, Zou T, Qin W, et al. Inhibition of EGFR overcomes acquired lenvatinib resistance driven by STAT3\u2013ABCB1 signaling in hepatocellular carcinoma. Cancer Res. 2022;82(20):3845\u201357.","journal-title":"Cancer Res"},{"key":"3760_CR25","doi-asserted-by":"publisher","first-page":"1192777","DOI":"10.3389\/fphar.2023.1192777","volume":"14","author":"K Yuan","year":"2023","unstructured":"Yuan K, Zhao S, Ye B, et al. A novel T-cell exhaustion-related feature can accurately predict the prognosis of OC patients. Front Pharmacol. 2023;14:1192777.","journal-title":"Front Pharmacol"},{"issue":"19","key":"3760_CR26","first-page":"7091","volume":"26","author":"Q Cao","year":"2022","unstructured":"Cao Q, Zhang Q, Zhou KX, et al. Lung cancer screening study from a smoking population in Kunming. Eur Rev Med Pharmacol Sci. 2022;26(19):7091\u20138.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3760_CR27","unstructured":"Jin ZC, Chen JJ, Zhu XL et al. Immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody\/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine, 2024, 72."},{"key":"3760_CR28","doi-asserted-by":"crossref","unstructured":"Wang W, Zhang Q, Cui Y et al. TRACE model: predicting treatment response to transarterial chemoembolization in unresectable hepatocellular carcinoma. J Hepatocellular Carcinoma, 2025: 193\u2013203.","DOI":"10.2147\/JHC.S490226"},{"issue":"2","key":"3760_CR29","doi-asserted-by":"publisher","first-page":"e1543","DOI":"10.1002\/ctm2.1543","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen Y, Gao Z, Mohd-Ibrahim I, et al. Pan\u2010cancer analyses of bromodomain containing 9 as a novel therapeutic target reveals its diagnostic, prognostic potential and biological mechanism in human tumours. Clin Translational Med. 2024;14(2):e1543.","journal-title":"Clin Translational Med"},{"issue":"6","key":"3760_CR30","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00270-024-03724-x","volume":"47","author":"JX Zhang","year":"2024","unstructured":"Zhang JX, Cheng Y, Wei J, et al. Transarterial chemoembolization combined with tyrosine kinase inhibitors plus immune checkpoint inhibitors versus tyrosine kinase inhibitors plus immune checkpoint inhibitors in unresectable hepatocellular carcinoma with first-or lower-order portal vein tumor thrombosis. Cardiovasc Interv Radiol. 2024;47(6):751\u201361.","journal-title":"Cardiovasc Interv Radiol"},{"issue":"5","key":"3760_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.4274\/dir.2021.211255","volume":"29","author":"HT Ball\u0131","year":"2023","unstructured":"Ball\u0131 HT, Aikimbaev K, Burak \u0130G, et al. Short-term changes of angiogenesis factors after transarterial radioembolization in hepatocellular carcinoma patients. Diagn Interventional Radiol. 2023;29(5):704.","journal-title":"Diagn Interventional Radiol"},{"issue":"6","key":"3760_CR32","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1002\/tox.24205","volume":"39","author":"C Jiang","year":"2024","unstructured":"Jiang C, Zhang S, Jiang L, et al. Precision unveiled: synergistic genomic landscapes in breast cancer\u2014Integrating single-cell analysis and decoding drug toxicity for elite prognostication and tailored therapeutics. Environ Toxicol. 2024;39(6):3448\u201372.","journal-title":"Environ Toxicol"},{"key":"3760_CR33","doi-asserted-by":"crossref","unstructured":"Lu D, Zhou L, Zuo Z et al. MRI radiomics to predict early treatment response to TACE combined with lenvatinib plus a PD-1 inhibitor for hepatocellular carcinoma with portal vein tumor thrombus. J Hepatocellular Carcinoma, 2025: 985\u201398.","DOI":"10.2147\/JHC.S513696"},{"key":"3760_CR34","unstructured":"Zhu HD, Li HL, Huang MS et al. Transarterial chemoembolization with PD-(L) 1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct. Target. Ther. 2023;8(1): 58."},{"key":"3760_CR35","doi-asserted-by":"publisher","first-page":"e16173","DOI":"10.7717\/peerj.16173","volume":"11","author":"Y You","year":"2023","unstructured":"You Y, Chen Y, Zhang Q, et al. Systematic and meta-based evaluation of the relationship between the built environment and physical activity behaviors among older adults. PeerJ. 2023;11:e16173.","journal-title":"PeerJ"},{"issue":"3","key":"3760_CR36","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00262-025-03962-z","volume":"74","author":"Z Ren","year":"2025","unstructured":"Ren Z, Wang Y, Jiang D, et al. PD1\u2009+\u2009Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma. Cancer Immunol Immunother. 2025;74(3):109.","journal-title":"Cancer Immunol Immunother"},{"issue":"5","key":"3760_CR37","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.dld.2023.09.019","volume":"56","author":"E Pinto","year":"2024","unstructured":"Pinto E, Pelizzaro F, Cardin R, et al. HIF-1\u03b1 and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization. Dig Liver Disease. 2024;56(5):872\u20139.","journal-title":"Dig Liver Disease"},{"key":"3760_CR38","doi-asserted-by":"crossref","unstructured":"Kuehu DL, Fu Y, Nasu M et al. Use of microalgae-derived astaxanthin to improve cytoprotective capacity in the ileum of heat-induced oxidative stressed broilers. Animals, 2024, 14(13): 1932.","DOI":"10.3390\/ani14131932"},{"key":"3760_CR39","doi-asserted-by":"publisher","first-page":"1371682","DOI":"10.3389\/fendo.2024.1371682","volume":"15","author":"Wang Hailin","year":"2024","unstructured":"Wang H, et al. Early-life undernutrition, immune dysregulation, and cancer incidence in later life: a national life-course analysis from the China health and retirement longitudinal study. Front Immunol. 2025;16:1602290. https:\/\/doi.org\/10.3389\/fimmu.2025.1602290.","journal-title":"Front Endocrinol"},{"issue":"10474","key":"3760_CR40","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(24)02575-3","volume":"405","author":"M Kudo","year":"2025","unstructured":"Kudo M, Ren Z, Guo Y, et al. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025;405(10474):203\u201315.","journal-title":"Lancet"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-03760-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-03760-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T11:39:59Z","timestamp":1763984399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-03760-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3760"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-03760-0","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"6 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Informed consent was obtained from all patients included in this study prior to submission of data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2157"}}